Skip to content

The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients

The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019277
Enrollment
Unknown
Registered
2018-11-02
Start date
2018-11-01
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Treatment group 1:Zoledronate Acid(ZA)
Treatment group 2:MTX+Zoledronate Acid

Sponsors

Shanghai Traditional Medicine University Affiliated Guanghua Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The consent to participation was obtained from patients who were clearly diagnosed as rheumatoid arthritis andeither: 1) L1-L4 or hip T value =-2.5 in BMD measurement plus obvious low back pain, night convulsions and limited life function symptoms, or 2) L1-L4 or hip joint T value = -1.5, = -2.5 in BMD measurement plus obvious low back pain, night convulsions and limited life function symptoms, with previous one or more fracture history.

Exclusion criteria

Exclusion criteria: (1) severe primary diseases in cardiovascular, cerebrovascular, liver, kidney and hematopoietic system, consumptive chronic diseases, or mental illness; (2) hypercalcemia, fresh fractures, liver or kidney dysfunction, thyroid-related diseases (such as hypothyroidism, hyperthyroidism), or malignant tumors; (3) other joint-involving rheumatic diseases, such as systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, ankylosing spondylitis, gout, etc; (4) allergy to the test drug zoledronate, or history of other allergies; (5) pregnancy, breastfeeding, or planning to become pregnant in the near future; (6) currently participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
CRP;ESR;BMD;

Secondary

MeasureTime frame
Morning time;Patient and doctor evaluation;

Countries

China

Contacts

Public ContactXiao Lianbo

Shanghai Traditional Medicine University Affiliated Guanghua Hospital

xiaolianbo199@126.com+86 021 62805833

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026